biostudies-literatureFu YNatural Science Foundation of Beijing MunicipalityBeijing Outstanding Young Scientist ProgramNational Natural Science Foundation of ChinaFund for Beijing Science & Technology Development of TCMCAMS Initiative for Innovative Medicine15938https://www.ebi.ac.uk/biostudies/studies/S-EPMC9786790biostudies-literatureUnknown23(24)Voglibose is an α-glycosidase inhibitor that improves postprandial hyperglycemia and increases glucagon-like peptide-1 (GLP-1) secretion in patients with type 2 diabetes. Recently, there has been increasing interest in the anti-inflammatory effects of voglibose on the intestine, but the underlying mechanism is not clear. This study evaluated the effects and mechanisms of voglibose on glycemic control and intestinal inflammation. Type 2 diabetic KKAy mice were treated with voglibose (1 mg/kg) by oral gavage once daily. After 8 weeks, glucose metabolism, levels of short-chain fatty acids (SCFAs), systematic inflammatory factors, intestinal integrity and inflammation were evaluated using hematoxylin and eosin staining, immunohistochemistry, immunofluorescence and Western blot analysis. VoglibInternational journal of molecular sciencesVoglibose Regulates the Secretion of GLP-1 Accompanied by Amelioration of Ileal Inflammatory Damage and Endoplasmic Reticulum Stress in Diabetic KKAy Mice.PMC9786790JJ-2020-252022-I2M-2-002BJJWZYJH0120191002302872021372021-I2M-1-026819004802022-I2M-JB001181973379Lei LLi CCao HChen LHuan YFu YLiu QLi PZhang LLiu SFeng CShen ZJi WGao XZhai JfalseVoglibose Regulates the Secretion of GLP-1 Accompanied by Amelioration of Ileal Inflammatory Damage and Endoplasmic Reticulum Stress in Diabetic KKAy Mice.Voglibose is an α-glycosidase inhibitor that improves postprandial hyperglycemia and increases glucagon-like peptide-1 (GLP-1) secretion in patients with type 2 diabetes. Recently, there has been increasing interest in the anti-inflammatory effects of voglibose on the intestine, but the underlying mechanism is not clear. This study evaluated the effects and mechanisms of voglibose on glycemic control and intestinal inflammation. Type 2 diabetic KKAy mice were treated with voglibose (1 mg/kg) by oral gavage once daily. After 8 weeks, glucose metabolism, levels of short-chain fatty acids (SCFAs), systematic inflammatory factors, intestinal integrity and inflammation were evaluated using hematoxylin and eosin staining, immunohistochemistry, immunofluorescence and Western blot analysis. Voglib2022-01-01T00:00:00Z2022 Dec2026-04-29T03:22:28.721Z2025-04-07T02:58:21.79ZS-EPMC97867903655558010.3390/ijms232415938